17 August 2009 in Bone Marrow Transplantation
1 September 1998 in American Journal of Respiratory and Critical Care Medicine
Although hematopoietic stem cell transplantation (HSCT) can be curative in patients with certain malignancies, survival is poor if the recipient becomes critically ill. This prospective study examined the outcomes of 115 consecutive HSCT patients admitted to the medical intensive care unit (MICU) of a tertiary cancer center and identified variables associated with survival. The need for endotracheal intubation and mechanical ventilation (“intubation”) had a profound adverse effect on survival. Overall, 9 of 48 (18.8%) intubated patients survived compared with a survival rate of 44 of 67 (65.7%) among patients not intubated (p < 0.001). This pattern persisted for nearly all patient subgroups. Among intubated patients, those receiving peripheral blood stem cell transplant (PBSCT) had significantly better survival than bone marrow transplant (BMT) patients (8 of 26, 31% versus 1 of 22, 4%; p = 0.028). Multiple logistic regression analyses indicated that the probability a patient admitted to the MICU survived decreased significantly if the patient was intubated, had an allogeneic rather than autologous transplant, had an infection or gastrointestinal bleeding, and also decreased with higher respiratory rate, higher heart rate, longer time from transplant to MICU admission or higher bilirubin. These results may be of value in deciding which critically ill patients will benefit from intubation following major complications after HSCT transplantation.
1 January 1994 in American Journal of Physiology-Cell Physiology
Human epidermal cells exhibited none of the cytosolic lipoxygenase activity that is prominent in mucosal epithelial cells, but instead contained a microsomal activity that converted arachidonic acid to 12-hydroxyeicosatetraenoic acid (12-HETE). Identification of the extractable 12-HETE-forming activity as a 12-lipoxygenase (distinct from cytochrome P-450) included (S)-12-stereospecificity of product formation, trapping of 12-hydroperoxyeicosatetraenoic acid as an intermediate reaction product, and lack of NADPH dependence for activity. Epidermal cell poly(A)+ RNA contained high levels of a 2.3-kb mRNA that selectively hybridized with human platelet 12-lipoxygenase cDNA, and partial cDNA sequence of this mRNA indicated identity to platelet 12-lipoxygenase. The epidermal 12-lipoxygenase was not recognized by antibodies against the leukocyte-type 12- and 15-lipoxygenases (found in leukocytes, reticulocytes, and mucosal epithelial cells) but was detected by an antiplatelet 12-lipoxygenase antibody. The epidermal 12-lipoxygenase antigen was selectively expressed in germinal layer keratinocytes in healthy and psoriatic skin, and these layers exhibited hyperplasia and increased immunostaining in inflamed psoriatic skin. Together with previous results, these observations indicate that 1) epidermis generates 12-HETE by either cytochrome P-450 or lipoxygenase-based mechanisms depending on reaction conditions, and 2) 12-lipoxygenases (originally described in hematopoietic cell types) may be expressed in at least two distinct isoforms in epithelial barriers in humans, and in the case of the skin, a microsomal (platelet-type) 12-lipoxygenase is selectively overexpressed in germinal layer keratinocytes during psoriatic inflammation.
1 July 2010 in Current Opinion in Pulmonary Medicine
Over the last decade, evidence-based support for pulmonary rehabilitation in the management of patients with chronic lung disease has grown tremendously. A beneficial role of pulmonary rehabilitation has been largely shown among patients with chronic obstructive pulmonary disease and in patients with pulmonary emphysema enlisted for lung volume reduction surgery. In these settings, significant reductions in dyspnea, and improvements in exercise performance and health-related quality of life have been clearly demonstrated following a program of pulmonary rehabilitation. Pulmonary rehabilitation is often advocated as an adjunctive intervention in patients with cancer; however, the benefits of this intervention in the cancer setting, particularly in the perioperative setting for lung cancer, are only recently emerging. This review summarizes these investigations and highlights ongoing controversies regarding the utility of pulmonary rehabilitation in the surgical and medical management of patients with lung cancer. Recent small studies suggest that pulmonary rehabilitation may favorably impact lung cancer management by improving a variety of clinically meaningful outcomes such as performance status, chemotherapy-related fatigue, oxygen consumption, exercise tolerance, and health-related quality of life. These findings, although intriguing, have not been investigated in any large, controlled trials to determine their impact, if any, on surgical resectability and outcome or on tolerance to aggressive chemoradiation therapy regimens. Pulmonary rehabilitation shows promise as a therapeutic intervention in the management of lung cancer. Further, well designed, adequately powered studies, however, are urgently needed to address outstanding questions about its exact role in guiding lung cancer management.
1 April 1993 in American Review of Respiratory Disease
We have previously described the distribution of the arachidonate 15-lipoxygenase in lung tissue obtained from healthy human subjects. In the present study, we have utilized the same immunohistochemical methodology to examine the expression of 15-lipoxygenase in bronchial biopsy tissue from subjects with airway disease. Immunohistochemistry of bronchial tissue using two antibodies against distinct epitopes of the 15-lipoxygenase and indirect biotin-avidin-peroxidase detection demonstrated that, in contrast to airway tissue from normal subjects (n = 10) in which 15-lipoxygenase antigen was confined to the uppermost airways (nose and trachea) and was almost undetectable in bronchi, the bronchial tissue obtained from subjects with asthma (n = 7) or chronic bronchitis (n = 7) exhibited markedly positive immunostaining of mucosal epithelial cells with both anti-15-lipoxygenase antibodies. Specificity of 15-lipoxygenase immunostaining was verified by antigen competition experiments and by the lack of immunostaining with preimmune serum or control anti-5-lipoxygenase antibodies. The increased levels of 15-lipoxygenase antigen in the bronchial epithelial cells of asthmatic and bronchitic subjects compared with the same cell population in normal subjects coupled with the previous findings of increased 15-lipoxygenase activity in asthmatic airways suggest that epithelial 15-lipoxygenase is induced by airway inflammatory disease.